IAN:CA:CNSX-iAnthus Capital Holdings Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.025

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

7.82K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

N/A

USD 3.91B
TRUL:CA Trulieve Cannabis Corp

N/A

USD 2.38B
CL:CA Cresco Labs Inc

N/A

USD 0.75B
AYR-A:CA Ayr Wellness Inc

N/A

USD 0.32B
PLTH:CA Planet 13 Holdings Inc

N/A

USD 0.22B
AAWH-U:CA Ascend Wellness Holdings Inc.

N/A

USD 0.20B
GRIN:CA Grown Rogue International Inc

N/A

USD 0.20B
JUSH:CA Jushi Holdings Inc

N/A

USD 0.15B
FFNT:CA 4Front Ventures Corp

N/A

USD 0.10B
MRMD:CA MariMed Inc.

N/A

USD 0.10B

ETFs Containing IAN:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -28.57% 39% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.57% 39% F 44% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -99.41% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.41% 7% C- 2% F
Average Annual (5 Year Horizon)  
Capital Gain -29.28% 42% F 27% F
Dividend Return -29.28% 42% F 27% F
Total Return N/A 29% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 106.54% 17% F 18% F
Risk Adjusted Return -27.48% 66% D+ 57% F
Market Capitalization 0.17B 93% A 99% N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.